|
Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962. |
|
|
Consulting or Advisory Role - Astellas Oncology; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck; Novartis; Roche |
Research Funding - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Astellas Oncology; Janssen |
|
|
Honoraria - Bristol-Myers Squibb; Celgene; Merck; Novartis; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Novartis; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Merck; Novartis; Roche |
Research Funding - Celgene; Merck; MSD |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Merck; Novartis; Roche |
|
Maria Teresa Curiel Garcia |
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche |
Expert Testimony - Bristol-Myers Squibb; MSD; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Leadership - Bristol-Myers Squibb |
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Roche |
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche |